BioSpace News Archive

Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease to Dyne Therapeutics.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Agencja Badań Medycznych, awarded a grant equivalent to $1.5 million USD to the Maria Sklodowska-Curie National Research Institute to fund a Phase 1B/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.

Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has granted a conditional marketing authorization (CMA) to Sinovac for CoronaVac,

Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Caigan Du, Associate Professor at the University of British Columbia to the Company’s Scientific Advisory Board.

Clubhouse Media Group, Inc. (OTCMKTS: CMGR) (“Clubhouse Media” or the “Company”), an influencer-based marketing and media firm with a global aggregate social media reach of over 100 million followers, is pleased to announce the closing of the Company’s acquisition of Magiclytics, the world’s first Revenue Prediction Software platform for influencer-based marketing.

Building on the successful hospital-focused launch of NUZYRA, Paratek is expanding commercial promotion of NUZYRA into the community setting aimed at addressing a significant unmet need for an effective, safe and well-tolerated once-daily oral antibiotic

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021

Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced that funds affiliated with Blackstone Tactical Opportunities, elected to convert 50,000 shares of 4.0% Series C Convertible Preferred Stock of Cryoport into common stock of Cryoport pursuant to the Preferred Stock certificate of designations.

Dalrada Financial Corp. (OTCQB: DFCO, “Dalrada”) is pleased to announce to its shareholders and the public that Mr. Anthony Zolezzi has accepted an appointment to Dalrada’s Board of Directors.

Thermo Fisher Scientific, the world leader in serving science, today launched its CE-IVD-Marked, Applied Biosystems TaqPath COVID–19 HT Kit that is compatible with the Amplitude platform.